Abstract:Background Tuberculosis (TB) remains a major public health concern worldwide. Previous studies have demonstrated that IL-17 plays an important role in initial immune response and is involved in both immune-mediated protection and pathology following infection with Mycobacterium tuberculosis (MTB). However, the alterations and regulation of plasma IL-17 level during TB treatment remain unclear. Moreover, the cell type responsible for the production of IL-17 in TB patients requires further study. Methods A total of 20 acid-fast bacilli smear-positive (AFB-positive) pulmonary TB patients and 20 age- and gender-matched healthy volunteers were included in our study. Blood samples were collected in heparinized tubes at the time of diagnosis (AFB-positive group) and 3 weeks after the initiation of therapy, when the sputum smear conversion (AFB-negative group) occurred, followed by symptomatic improvement. IL-17 levels and IL-17-producing cells in PBMCs were detected. Lymphocyte populations in the peripheral blood between the AFB-positive and AFB-negative groups were compared by flow-cytometry. A549 cells, a cell line of alveolar epithelial cells, were applied to determine the extent of the pathological damage mediated by IL-17 following MTB infection. Recombinant human IL-10 was used to investigate the regulation of IL-17 expression after sputum smear conversion in AFB-positive pulmonary TB patients. Results Plasma IL-17 level were elevated in patients with sputum AFB-positive pulmonary TB, but substantially decreased after TB treatment and smear conversion. Our data indicate that NKT-like cells might be the main source of IL-17, in addition to conventional T cells in AFB-positive pulmonary TB patients. The secretion of IL-17 may be suppressed by regulatory T (Treg) cells and IL-10 during TB treatment. Moreover, the IL-17 levels were positively correlated to both the C-reactive protein and erythrocyte sedimentation rate. Therefore, IL-17 was capable of alveolar epithelial cell damage following MTB infection. Conclusion The increase in the frequency of Treg cells and IL-10 levels was associated with a decrease in IL-17 in patients receiving TB treatment. Thus, IL-10 and Tregs may function to inhibit immune-mediated pathology in TB patients.

IL-32 is a molecular marker of a host defense network in human tuberculosis

The Biology and Role of Interleukin-32 in Tuberculosis

The regulation and potential role of interleukin-32 in tuberculous pleural effusion

An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis

Interleukin-26 expression in tuberculosis disease and its regulatory effect in macrophage polarization and intracellular elimination of Mycobacterium tuberculosis

A novel genetic association of IL32 with tuberculosis

Decreased IL-17 during treatment of sputum smear-positive pulmonary tuberculosis due to increased regulatory T cells and IL-10

Interleukin‐32ε induces caspase‐independent apoptosis mediated by N‐Myc interactor in macrophages infected with Mycobacterium tuberculosis

IL-37 Confers Protection Against Mycobacterial Infection Involving Suppressing Inflammation and Modulating T Cell Activation

Novel role for IL-22 in protection during chronic Mycobacterium tuberculosis HN878 infection

Selective Destruction of Interleukin 23-Induced Expansion of a Major Antigen-Specific γδ T-Cell Subset in Patients With Tuberculosis.

MicroRNA-31 Mediated by Interferon Regulatory Factor 7 Signaling Facilitates Control of Mycobacterium Tuberculosis Infection

An Interferon-Related Signature in the Transcriptional Core Response of Human Macrophages to Mycobacterium Tuberculosis Infection.

Mesenchymal-epithelial Transition Factor Regulates Monocyte Function During Mycobacterial Infection Via Indoleamine 2,3-Dioxygenase

Interleukin-10 Family and Tuberculosis: An Old Story Renewed.

Increased Frequency of ILT2-expressing CD56dimCD16+ NK Cells Correlates with Disease Severity of Pulmonary Tuberculosis

LILRB1-HLA-G axis defines a checkpoint driving natural killer cell exhaustion in tuberculosis

Aberrant plasma IL-7 and soluble IL-7 receptor levels indicate impaired T-cell response to IL-7 in human tuberculosis

A Derived Network-Based Interferon-Related Signature of Human Macrophages Responding to Mycobacterium Tuberculosis.

Interleukin 24 As a Novel Potential Cytokine Immunotherapy for the Treatment of Mycobacterium Tuberculosis Infection.

Mycobacterium tuberculosis hijacks host macrophages-derived interleukin 16 to block phagolysosome maturation for enhancing intracellular growth